The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 2024
Filed:
Jan. 29, 2020
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts, Heidelberg, DE;
Jörg Willuda, Glienicke/Nordbahn, DE;
Mark Trautwein, Whippany, NJ (US);
Uwe Gritzan, Cologne, DE;
Christoph Freiberg, Wuppertal, DE;
Frank Dittmer, Düsseldorf, DE;
Dorian Schönfeld, Cologne, DE;
Julian Marius Glück, Meerbusch, DE;
Jessica Pinkert, Wuppertal, DE;
Eva-Maria Gutierrez, Illertissen, DE;
Sven Golfier, Berlin, DE;
Simon Holton, Berlin, DE;
Philip Beckhove, Heidelberg, DE;
Yingzi Ge, Wiesloch, DE;
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Heidelberg, DE;
Abstract
The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human andCEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.